Design of the ZUMA-1 Trial in Non-Hodgkin Lymphoma

New findings reveal that fixed-duration ibrutinib plus venetoclax offers long-term efficacy and safety for patients with untreated chronic lymphocytic leukemia.

ALLO-316 shows promising results in advanced renal cell carcinoma, with a 25% response rate and rapid treatment turnaround, paving the way for future studies.

During a live event, Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and response to treatment based on mutational analyses.

Luspatercept-aamt shows significant survival benefits and transfusion independence in lower-risk MDS, reshaping treatment standards in hematology.

A new study reveals that rectal spacers during prostate cancer radiation therapy significantly reduce long-term erectile dysfunction rates, enhancing patient outcomes.